Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Refinex is a brand of botulinum toxin type A, a potent neurotoxic protein derived from the Hall strain of the bacterium *Clostridium botulinum*. It functions as a neuromuscular blocking agent by entering peripheral cholinergic nerve terminals and enzymatically cleaving SNAP-25, a protein essential for the docking and fusion of acetylcholine-containing vesicles with the presynaptic membrane. This action effectively inhibits the release of the neurotransmitter acetylcholine at the neuromuscular junction, leading to temporary chemical denervation and localized muscle relaxation or paralysis. Refinex is utilized in both therapeutic and aesthetic medicine for indications such as the reduction of dynamic facial wrinkles (e.g., glabellar lines, crow's feet), the management of blepharospasm, hemifacial spasm, cervical dystonia, and specialized procedures like the treatment of excessive gingival display (gummy smile).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on botulinum toxin type A (KC Pharmaceutical).